Compound · clinical trials

Durvalumab clinical trials

Also listed in trial records as MEDI 4736, Imfinzi, MEDI4736, Durvalumab / Tremelimumab Combination Therapy, Tremelimumab: CP-675, MEDI4736 (Durvalumab), MEDI4736 & IMFINZI, Imfinz, Other Name: MEDI4736, Durvalumab with etoposide and Carboplatin/Cisplatin, Immunoglobulin G1

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 220 trials in our USA, South Korea, France, Spain, Canada, Italy, China, Germany, Taiwan, Japan, Poland, Australia, Brazil, UK, Belgium, Turkey, Netherlands, Mexico, Israel, India, Austria, Switzerland, Singapore, Czechia, Portugal, Denmark, Sweden, Egypt, Ireland and Norway registers that name Durvalumab as an intervention. Synced 12 Nov 2026

220Current trials

84Recruiting now

94Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov registry records · Synced 12 Nov 2026 · Editorial standards

At a glance

Durvalumab is named as an intervention in 220 current clinical trials in our USA, South Korea, France, Spain, Canada, Italy, China, Germany, Taiwan, Japan, Poland, Australia, Brazil, UK, Belgium, Turkey, Netherlands, Mexico, Israel, India, Austria, Switzerland, Singapore, Czechia, Portugal, Denmark, Sweden, Egypt, Ireland and Norway registers. 84 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (70). The most-studied condition is Hepatocellular Carcinoma. The EU clinical trials register (CTIS) separately lists 11 authorised or ongoing trials.

Durvalumab also has an approved-drug profile on this site (FDA label data): Imfinzi (Durvalumab) →

Where Durvalumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Durvalumab was the US, on 1 May 2017. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

1 May 2017

Imfinzi

BLA761069 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

21 Sep 2018

Imfinzi

EMA product page

First centralised authorisation

CACanada (Health Canada)

3 Nov 2017

Imfinzi

Notice of Compliance 20026

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Durvalumab

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$120.4m

18,115 prescriptions in 2025 · Imfinzi

+17% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Durvalumab works

All drug targets →

Programmed cell death 1 ligand 1 inhibitor Inhibitor
Target: CD274 CD274 molecule
ChEMBL only

Other medicines acting on CD274

Atezolizumab Adebrelimab Avelumab Envafolimab Sugemalimab KN046 Danburstotug Bintrafusp alfa

Diseases it has been tested for in clinical trials, by furthest phase

Biliary tract cancerPhase 3
Breast cancerPhase 3
CancerPhase 3
Cervical cancerPhase 3
Endometrial cancerPhase 3
Esophageal squamous cell carcinomaPhase 3
Fallopian tube cancerPhase 3
Gastric cancerPhase 3
Head and neck squamous cell carcinomaPhase 3
Liver cancerPhase 3

134 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3301587, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7985, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Durvalumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 11 technology appraisals of Durvalumab. 11 are current, and 9 of these recommend it for at least some patients.

Appraisal	NICE recommendation	Published	Status
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer NICE TA1190	Optimised Not recommended	9 Sep 2026	Current
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma NICE TA1160	Recommended	3 Jun 2026	Current
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer NICE TA1138	Recommended	2 Mar 2026	Current
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy NICE TA1099	Recommended	1 Oct 2025	Current
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma NICE TA1090	Recommended	19 Aug 2025	Current
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer NICE TA1041	Optimised	19 Feb 2025	Current
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer NICE TA1030	Recommended	15 Jan 2025	Current
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer NICE TA944	Recommended	10 Jan 2024	Current

See all 11 appraisals →

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Durvalumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 1 product on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Imfinzi
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Durvalumab

ATC code: L01XC28
ChEMBL: CHEMBL3301587
DrugBank: DB11714
CAS number: 1428935-60-7
FDA UNII: 28X28X9OKV
Wikidata: Q19904005
Wikipedia: Durvalumab

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting8438%
Not yet open73%
Active, closed12758%
By invitation21%

Trials by phase

Phase 210749%
Phase 36128%
Phase 12210%
Phase 1/2199%
Observational52%
Phase 2/342%
Not applicable10%
Phase 410%

Clinical trials of Durvalumab

220 trials

Study	Phase	Status	Lead sponsor	Registers
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie NCT06031233 · ClinicalTrials.gov ↗ · Oncology, Infusion Reaction	Phase 4	Recruiting	Isala	Netherlands
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features NCT05255653 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	Leiden University Medical Center	Germany, France, Italy, Netherlands, Belgium, Czechia, Canada
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer NCT06058377 · ClinicalTrials.gov ↗ · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Israel
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer NCT06282575 · Biliary Tract Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Israel
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial NCT06498635 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Eli Lilly and Company	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial NCT07166406 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) NCT07221253 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) NCT07229625 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) NCT07361497 · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) NCT07554339 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Brazil, Japan, South Korea, Taiwan, Australia
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer NCT07710885 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Taiho Pharmaceutical Co., Ltd	Japan, South Korea, Australia
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. NCT07877818 · ClinicalTrials.gov ↗ · Gastric, Esophagogastric Junction	Phase 3	Recruiting	AstraZeneca	China
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer NCT04628767 · ClinicalTrials.gov ↗ · Renal Pelvis and Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
Radiation Therapy in Unresectable Gall Bladder Cancer NCT06214572 · Gall Bladder Cancer	Phase 2/3	Recruiting	Tata Memorial Centre	India
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma NCT06904170 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Recruiting	UNICANCER	France
The Drug Rediscovery Protocol (DRUP Trial) NCT02925234 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasm	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies NCT03847649 · ClinicalTrials.gov ↗ · Cancer	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC NCT04644289 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer	Phase 2	Recruiting	AGO Research GmbH	Germany
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer NCT04918186 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer NCT05061550 · Non-small Cell Lung Cancer	Phase 2	Recruiting	AstraZeneca	Ireland, USA, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, South Korea, Taiwan
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy NCT05222971 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, DNA Damage Repair Deficiency	Phase 2	Recruiting	Asan Medical Center	South Korea
Durvalumab and Tremelimumab in Resectable HCC NCT05440864 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	University Health Network, Toronto	Spain, Italy, Canada
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab NCT05568212 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer Patients	Phase 2	Recruiting	Fondazione Ricerca Traslazionale	Italy
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel NCT05582538 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Metastatic	Phase 2	Recruiting	IFOM ETS - The AIRC Institute of Molecular Oncology	Italy
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) NCT05620628 · ClinicalTrials.gov ↗ · Stomach Cancer, Adenocarcinoma	Phase 2	Recruiting	Jeeyun Lee	South Korea
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer NCT05640791 · ClinicalTrials.gov ↗ · Resectable Biliary Tract Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949 · ClinicalTrials.gov ↗ · Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable	Phase 2	Recruiting	Beth Israel Deaconess Medical Center	Israel
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC NCT05720260 · ClinicalTrials.gov ↗ · Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598 · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Recruiting	Replimune, Inc	USA
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) NCT05742607 · Non Small Cell Lung Cancer	Phase 2	Recruiting	Innate Pharma	USA, France, Poland
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) NCT05845450 · ClinicalTrials.gov ↗ · Colorectal Cancer, Resectable Colorectal Carcinoma	Phase 2	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
Durvalumab and Oleclumab in Resectable PDAC NCT06060405 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	University Health Network, Toronto	Canada
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC NCT06223711 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Universität des Saarlandes	Germany
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study NCT06290505 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Australasian Gastro-Intestinal Trials Group	Australia
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma NCT06341764 · ClinicalTrials.gov ↗ · Cholangiocarcinoma	Phase 2	Recruiting	National Cancer Institute, Naples	Italy
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) NCT06371482 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy NCT06375915 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Francesco De Cobelli	Italy
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816 · ClinicalTrials.gov ↗ · Large Cell Neuroendocrine Carcinoma of the Lung	Phase 2	Recruiting	Centre Leon Berard	France
Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) NCT06418087 · ClinicalTrials.gov ↗ · Pulmonary Large-cell Neuroendocrine Carcinoma	Phase 2	Recruiting	Gruppo Oncologico Italiano di Ricerca Clinica	Italy
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma NCT06440993 · ClinicalTrials.gov ↗ · Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA	Phase 2	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) NCT06441747 · ClinicalTrials.gov ↗ · Cholangiocarcinoma	Phase 2	Recruiting	Australasian Gastro-Intestinal Trials Group	Australia
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA NCT06464068 · ClinicalTrials.gov ↗ · Extrapulmonary Small Cell Carcinoma	Phase 2	Recruiting	Gruppo Oncologico Italiano di Ricerca Clinica	Italy
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer NCT06591650 · ClinicalTrials.gov ↗ · Gallbladder Cancer Unresectable	Phase 2	Recruiting	Fudan University	China
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer NCT06630130 · ClinicalTrials.gov ↗ · Stomach Neoplasms	Phase 2	Recruiting	Jeeyun Lee	South Korea
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) NCT06667908 · Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	Johnson & Johnson Enterprise Innovation Inc	UK, USA, China, France, Spain, Netherlands, Turkey, Brazil, Australia, Israel
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen NCT06680050 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer NSCLC	Phase 2	Recruiting	Mario Negri Institute for Pharmacological Research	Italy, Switzerland
Single cEll pRofiling PErsistaNce To ImmuNothErapy NCT06680739 · Colorectal Cancer, Endometrial Cancer	Phase 2	Recruiting	Vall d'Hebron Institute of Oncology	Spain
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer NCT06708858 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 2	Recruiting	Dai, Guanghai	China
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial) NCT06859684 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab	Phase 2	Recruiting	West China Hospital	China
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma NCT06880523 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) NCT06960577 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate	Phase 2	Recruiting	AstraZeneca	France, Spain, Italy, Netherlands, Canada, Brazil, Australia
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999694 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab	Phase 2	Recruiting	Chang Gung Memorial Hospital	Taiwan
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999707 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab	Phase 2	Recruiting	Chang Gung Memorial Hospital	Taiwan
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma NCT07036380 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 2	Recruiting	Centre Hospitalier Universitaire de Besancon	France
Durvalumab as Consolidation for Patients LS-SCLC NCT07055581 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 2	Recruiting	Qian Chu	China
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis NCT07122089 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Recruiting	Center Eugene Marquis	France
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial NCT07288034 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8	Phase 2	Recruiting	City of Hope Medical Center	Egypt
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC NCT07459634 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Jazz Pharmaceuticals	USA
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma NCT07872722 · ClinicalTrials.gov ↗ · CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	National Cancer Center, Japan	Japan
A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy NCT07911280 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Samsung Medical Center	South Korea
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC NCT03694236 · ClinicalTrials.gov ↗ · Potentially Resectable Stage II/IIIa NSCLC	Phase 1/2	Recruiting	Yonsei University	South Korea
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI NCT04954599 · ClinicalTrials.gov ↗ · Unspecified Adult Solid Tumor, Protocol Specific	Phase 1/2	Recruiting	Maastricht University Medical Center	Spain, Netherlands, Belgium
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors NCT05187338 · ClinicalTrials.gov ↗ · Lung Cancer, Liver Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer NCT05886439 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) NCT06780137 · Small Cell Lung Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Turkey, Japan, South Korea, Taiwan, Australia, Israel
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma NCT06911255 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma	Phase 1/2	Recruiting	Yoon Jun Kim	South Korea
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer NCT07174583 · Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3	Phase 1/2	Recruiting	IDEAYA Biosciences	USA
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT03772561 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1	Recruiting	National University Hospital, Singapore	Singapore
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 1	Recruiting	AstraZeneca	USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma NCT05155189 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1	Recruiting	Zhejiang University	China
Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma NCT06470256 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 1	Recruiting	Zhiyong Huang	China
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Israel
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab NCT07391670 · ClinicalTrials.gov ↗ · Solid Tumours	Phase 1	Recruiting	AstraZeneca	Poland, South Korea, Taiwan, Australia
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) NCT07531095 · Small Cell Lung Cancer	Phase 1	Recruiting	Amgen	USA, Germany, France, Spain, Belgium, Poland, Switzerland, Turkey, Australia, Egypt
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation	Observational	Recruiting	Fundación GECP	Spain
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers NCT06611345 · ClinicalTrials.gov ↗ · Biliary Tract Cancers (BTC)	Not applicable	Recruiting	Jiangsu Healthy Life Innovation Medical Technology Co., Ltd	China
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC NCT06998719 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma	Phase 2	Not yet open	Bi Nan	China
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) NCT07247786 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Respiratory Tract Neoplasm	Phase 2	Not yet open	Fundación GECP	Spain
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma NCT07507968 · ClinicalTrials.gov ↗ · Esophagogastric Adenocarcinoma	Phase 2	Not yet open	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Spain
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial NCT07625930 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Not yet open	McGill University Health Centre/Research Institute of the McGill University Health Centre	Canada
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer NCT07759492 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III Unresectable	Phase 2	Not yet open	Intergroupe Francophone de Cancerologie Thoracique	France
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer NCT07269158 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy	Phase 1/2	Not yet open	Yonsei University	South Korea
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma NCT07904494 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable	Observational	Not yet open	Assiut University	Egypt
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab NCT05303532 · Cancer	Phase 3	By invitation	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) NCT06419179 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Phase 2	By invitation	University of Cologne	Germany
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) NCT02453282 · Non-Small-Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Canada, Japan, South Korea, Taiwan, Australia
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer NCT02516241 · Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) NCT02542293 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Sweden, Denmark, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Singapore, Israel
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) NCT03003962 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, China, Netherlands, Poland, Turkey, South Korea, Taiwan, Australia
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) NCT03043872 · Small Cell Lung Carcinoma Extensive Disease	Phase 3	Active, closed	AstraZeneca	USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). NCT03164616 · Non Small Cell Lung Cancer NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, Poland, Brazil, Mexico, Japan, South Korea, Taiwan
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma NCT03298451 · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Canada, Brazil, Japan, South Korea, Taiwan
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer NCT03528694 · Non-muscle-invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	UK, Germany, France, Spain, Netherlands, Belgium, Poland, Austria, Canada, Japan, Australia
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer NCT03682068 · Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Spain, Italy, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy NCT03703297 · Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Canada, Japan, South Korea, Taiwan
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients NCT03706690 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	AstraZeneca	India, China, Poland, Turkey, Mexico, South Korea, Taiwan
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC NCT03732677 · Muscle Invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients NCT03737643 · Advanced Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma NCT03778957 · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, India, China, France, Spain, Italy, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer NCT03800134 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation NCT03833154 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) NCT03875235 · Biliary Tract Neoplasms	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, France, Italy, Poland, Turkey, Japan, South Korea, Taiwan
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) NCT04116047 · Oropharyngeal Cancer	Phase 3	Active, closed	University of Birmingham	Ireland
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer NCT04269200 · Endometrial Neoplasms	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, Spain, Belgium, Poland, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC NCT04550260 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, China, France, Spain, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer NCT04592913 · Gastrointestinal Neoplasms, Esophagogastric Junction	Phase 3	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Netherlands, Belgium, Denmark, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) NCT04597671 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Association NVALT Studies	Netherlands
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy NCT04637594 · ClinicalTrials.gov ↗ · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin NCT04960709 · Muscle Invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC NCT05043090 · Papillary Renal Cell Carcinoma	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) NCT05170204 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Italy, Belgium, Sweden, Poland, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC NCT05211895 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer NCT05221840 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC NCT05301842 · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Belgium, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Egypt
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy NCT05450692 · Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC NCT05557838 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	China
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) NCT05629585 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Canada, Brazil, Japan, South Korea, Taiwan
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations NCT05687266 · NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Japan, South Korea, Singapore
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) NCT05883644 · Advanced Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Japan, South Korea, Singapore
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants NCT05943106 · Non-Muscle- Invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	USA
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab NCT06211036 · Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer	Phase 3	Active, closed	Amgen	Ireland, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain NCT06746116 · ClinicalTrials.gov ↗ · Advanced or Recurrent Endometrial Cancer	Phase 3	Active, closed	AstraZeneca	Spain
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. NCT06992609 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Phase 3	Active, closed	AstraZeneca	Spain
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer	Phase 3	Active, closed	Amgen	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel, Egypt
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) NCT06109272 · Hepatocellular Carcinoma	Phase 2/3	Active, closed	AbbVie	USA, China, France, Spain, Italy, Taiwan
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	UNICANCER	France
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma NCT02519348 · Hepatocellular Carcinoma	Phase 2	Active, closed	MedImmune LLC	USA, China, Spain, Italy, Japan, South Korea, Taiwan, Singapore
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer NCT02888743 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC NCT03057106 · ClinicalTrials.gov ↗ · Lung Cancer Metastatic	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada, Australia
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma	Phase 2	Active, closed	ImmunityBio, Inc	USA
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy NCT03334617 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Germany, France, Spain, Austria, Canada, South Korea, Israel
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC NCT03410615 · ClinicalTrials.gov ↗ · Oropharyngeal Squamous Cell Carcinoma	Phase 2	Active, closed	Canadian Cancer Trials Group	Spain, Italy, Belgium, Canada
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) NCT03459846 · Urinary Bladder Neoplasms	Phase 2	Active, closed	AstraZeneca	USA, Spain, Canada, South Korea, Taiwan, Egypt
1st Line Durvalumab in PS 2 NSCLC Patients NCT03620669 · ClinicalTrials.gov ↗ · NSCLC Stage IV, NSCLC Stage IIIB	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone NCT03660826 · ClinicalTrials.gov ↗ · Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. NCT03704480 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer NCT03768570 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Canadian Cancer Trials Group	Spain, Canada
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) NCT03775486 · Non-small Cell Lung Cancer NSCLC	Phase 2	Active, closed	AstraZeneca	UK, USA, India, Netherlands, Belgium, Poland, Mexico, Japan, South Korea
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors NCT03851614 · ClinicalTrials.gov ↗ · Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma	Phase 2	Active, closed	University Health Network, Toronto	Canada
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: NCT03875573 · ClinicalTrials.gov ↗ · Luminal B	Phase 2	Active, closed	Jules Bordet Institute	France, Belgium
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) NCT03944772 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Spain, Italy, Netherlands, Sweden, Denmark, Norway, Japan, South Korea
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC NCT03965468 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Stage IV, Oligometastasis	Phase 2	Active, closed	ETOP IBCSG Partners Foundation	Spain, Italy, Netherlands, Switzerland
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors NCT03991832 · ClinicalTrials.gov ↗ · Glioma, Cholangiocarcinoma, Solid Tumor	Phase 2	Active, closed	University Health Network, Toronto	Canada
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. NCT04053322 · ClinicalTrials.gov ↗ · ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status	Phase 2	Active, closed	UNICANCER	France
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss NCT04065269 · ClinicalTrials.gov ↗ · Gynaecological Cancers	Phase 2	Active, closed	Institute of Cancer Research, United Kingdom	Canada
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer NCT04176848 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial NCT04216290 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group NCT04230759 · ClinicalTrials.gov ↗ · Anal Cancer, Anal Carcinoma, Anal Cancer Stage III	Phase 2	Active, closed	Goethe University	Germany, Switzerland, Austria
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) NCT04238637 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) NCT04245514 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, NSCLC	Phase 2	Active, closed	Swiss Cancer Institute	Germany, Switzerland
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer NCT04308174 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms, Gallbladder Cancer, Cholangiocarcinoma	Phase 2	Active, closed	Asan Medical Center	South Korea
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. NCT04348045 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study NCT04392505 · ClinicalTrials.gov ↗ · Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III	Phase 2	Active, closed	Oslo University Hospital	Norway
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). NCT04472949 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Lung Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC NCT04522544 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable, HCC	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) NCT04602533 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 2	Active, closed	Michael Hopp	Germany
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800 · Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer NCT04742075 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Active, closed	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	Denmark
Study of AZD2811 + Durvalumab in ES-SCLC NCT04745689 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Spain, Poland, South Korea
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. NCT04817826 · ClinicalTrials.gov ↗ · Gastric Cancer, Microsatellite Instability	Phase 2	Active, closed	Gruppo Oncologico del Nord-Ovest	Italy
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours NCT04999969 · Locally Advanced or Metastatic Solid Tumours	Phase 2	Active, closed	AstraZeneca	USA, Spain, Canada, South Korea
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy NCT05000710 · ClinicalTrials.gov ↗ · Metastatic or Locally Advanced NSCLC	Phase 2	Active, closed	Sheba Medical Center	Israel
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition NCT05061134 · Melanoma	Phase 2	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Canada, South Korea, Australia
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC NCT05092412 · ClinicalTrials.gov ↗ · Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab	Phase 2	Active, closed	You Lu	China
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer NCT05198830 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) NCT05206812 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Yonsei University	South Korea
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) NCT05215106 · ClinicalTrials.gov ↗ · Early Small (cT1N0) Triple Negative Breast Cancer	Phase 2	Active, closed	Gustave Roussy, Cancer Campus, Grand Paris	France
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC NCT05374603 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Active, closed	AstraZeneca	China
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) NCT05451043 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer	Phase 2	Active, closed	AHS Cancer Control Alberta	Canada
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax NCT05617963 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Phase 2	Active, closed	UNICANCER	France
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery NCT05713838 · ClinicalTrials.gov ↗ · Esophagus Adenocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy NCT05796089 · ClinicalTrials.gov ↗ · Extensive-Stage Small-Cell Lung Cancer	Phase 2	Active, closed	Trans Tasman Radiation Oncology Group	Australia
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) NCT05856695 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Active, closed	Intergroupe Francophone de Cancerologie Thoracique	France
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) NCT05925530 · Non-small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Sweden, Austria, Czechia, Portugal, Canada
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS NCT06008093 · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	AstraZeneca	USA
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE NCT06040099 · Hepatocellular Carcinoma (HCC)	Phase 2	Active, closed	AstraZeneca	USA
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer NCT06094140 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Australasian Gastro-Intestinal Trials Group	Australia
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC NCT06490107 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma NCT07081633 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	AstraZeneca	China
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors NCT02671435 · Advanced Solid Tumors	Phase 1/2	Active, closed	MedImmune LLC	UK, USA, France, Spain, Italy, Belgium, Canada, South Korea, Australia
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. NCT02734004 · Ovarian, Breast, SCLC	Phase 1/2	Active, closed	AstraZeneca	UK, USA, France, Netherlands, Switzerland, South Korea, Israel
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer NCT03594396 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1/2	Active, closed	Seoul National University Hospital	South Korea
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC NCT03616886 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 1/2	Active, closed	Jules Bordet Institute	France, Belgium
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer NCT03742102 · Triple Negative Breast Neoplasms	Phase 1/2	Active, closed	AstraZeneca	UK, USA, Poland, Canada, South Korea, Taiwan
Durvalumab and Tremelimumab for Pediatric Malignancies NCT03837899 · Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies	Phase 1/2	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Netherlands
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC NCT04068610 · Metastatic Microsatellite-stable Colorectal Cancer	Phase 1/2	Active, closed	MedImmune LLC	USA, France, Spain, Canada, Australia
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer NCT04538742 · Metastatic Breast Cancer	Phase 1/2	Active, closed	AstraZeneca	UK, USA, India, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Australia
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy NCT05927142 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 1/2	Active, closed	Joachim Aerts, MD PhD	Netherlands
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation NCT06501625 · ClinicalTrials.gov ↗ · Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Phase 1/2	Active, closed	Institut de Recherches Internationales Servier	Germany, France, Spain, Canada, Brazil, Japan, South Korea, Australia
AZD9291 in Combination With Ascending Doses of Novel Therapeutics NCT02143466 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer	Phase 1	Active, closed	AstraZeneca	USA, Poland, Canada, Japan, South Korea, Taiwan
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents NCT02264678 · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	Phase 1	Active, closed	AstraZeneca	UK, USA, France, South Korea
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens NCT02537418 · Solid Malignancies	Phase 1	Active, closed	Canadian Cancer Trials Group	Canada
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer NCT02546661 · Muscle Invasive Bladder Cancer	Phase 1	Active, closed	AstraZeneca	UK, USA, France, Spain, Canada
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer NCT02826434 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Active, closed	Massachusetts General Hospital	Israel
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC NCT03819465 · Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AstraZeneca	USA, Spain, Belgium, Poland, Austria, South Korea, Taiwan
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations NCT03842228 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm	Phase 1	Active, closed	National Cancer Institute (NCI)	Israel
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations NCT04521686 · Cholangiocarcinoma, Chondrosarcoma, Glioma	Phase 1	Active, closed	Eli Lilly and Company	USA, China, France, Spain, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer NCT04556773 · Metastatic Breast Cancer	Phase 1	Active, closed	AstraZeneca	USA, France, Belgium, Canada, Brazil, Mexico, South Korea, Taiwan, Australia
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer NCT04612751 · Advanced or Metastatic NSCLC	Phase 1	Active, closed	AstraZeneca	USA, Spain, Italy, Belgium, Poland, Turkey, Japan, Taiwan
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395 · Extensive Stage Small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Canada, Japan, South Korea, Taiwan, Australia, Israel
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer NCT05411094 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours NCT05514132 · ClinicalTrials.gov ↗ · Advanced Solid Tumours	Phase 1	Active, closed	AstraZeneca	China
SIRT With Tremelimumab and Durvalumab for Resectable HCC NCT05701488 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer	Phase 1	Active, closed	Jiping Wang, MD, PhD	Israel
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) NCT06898957 · Small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA, China, Germany, France, Spain, Italy, Canada, South Korea
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. NCT05683977 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Observational	Active, closed	AstraZeneca	France
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery NCT06117891 · Unresectable Hepatocellular Carcinoma	Observational	Active, closed	Bayer	USA, China, France, Spain, Italy, Brazil, South Korea, Taiwan
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada NCT07718139 · Non-Small Cell Lung Cancer	Observational	Active, closed	Bristol-Myers Squibb	UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Durvalumab in the EU trials register (CTIS)

11 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Durvalumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinations in Adult Patients With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA) 2025-524836-21-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	AstraZeneca AB	Italy
A Phase 3, Open-label Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Experienced Disease Progression Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (HARMONi-10) 2026-526300-67-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Summit Therapeutics Inc	Greece, Italy, Germany + 2 more
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04). 2025-525030-57-00 · Neoplasms	Phase 3	Ongoing	AstraZeneca AB	Italy, Poland, Spain + 2 more
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL) 2025-524439-38-00 · Respiratory Tract Diseases	Phase 2	Authorised	Oslo Universitetssykehus HF	Sweden, Norway, Denmark
In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint 2026-526251-60-00 · Neoplasms	Phase 2	Authorised	Universitair Medisch Centrum Groningen	Netherlands
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS) 2026-525513-31-00 · Neoplasms	Phase 3	Authorised	Norges Teknisk-Naturvitenskapelige Universitet NTNU	Denmark, Finland, Estonia + 5 more
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI 2026-525898-39-00 · Neoplasms	Phase 3	Authorised	Azienda Sanitaria Locale Napoli 1 Centro	Italy
IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer 2025-522801-39-00 · Neoplasms	Phase 2	Authorised	Intergroupe Francophone De Cancerologie Thoracique	France
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer 2025-523438-24-00 · Neoplasms	Phase 1	Authorised	Ideaya Biosciences Inc	France, Spain
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) 2025-522038-29-00 · Neoplasms	Phase 3	Ongoing	Merck Sharp & Dohme LLC	Italy, Netherlands, France + 4 more
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2 2025-521608-23-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	IRCCS Istituto Nazionale Tumori Fondazione Pascale	Italy

Durvalumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Durvalumab on the HPRA medicines list.

IMFINZI 50 mg/ml concentrate for solution for infusion.AstraZeneca AB · EU/1/18/1322/001-002

All 1 Irish product →

Supply shortages

No entry for Durvalumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Durvalumab

223 conditions

Hepatocellular Carcinoma14 Biliary Tract Cancer9 Non-Small Cell Lung Cancer8 Carcinoma, Non-Small-Cell Lung7 Cholangiocarcinoma7 Non-small Cell Lung Cancer6 Small Cell Lung Cancer6 Breast Cancer6 Lung Cancer5 Metastatic Breast Cancer4 Cancer4 Non Small Cell Lung Cancer4

All 223 conditions

Condition (as registered)	Trials
Hepatocellular Carcinoma	14
Biliary Tract Cancer	9
Non-Small Cell Lung Cancer	8
Carcinoma, Non-Small-Cell Lung	7
Cholangiocarcinoma	7
Non-small Cell Lung Cancer	6
Small Cell Lung Cancer	6
Breast Cancer	6
Lung Cancer	5
Metastatic Breast Cancer	4
Cancer	4
Non Small Cell Lung Cancer	4
Hepatocellular Carcinoma (HCC)	4
Durvalumab	4
Small Cell Lung Carcinoma	4
Biliary Tract Neoplasms	3
Gastric Cancer	3
NSCLC	3
Muscle Invasive Bladder Cancer	3
Advanced Hepatocellular Carcinoma	3
Extensive-stage Small-cell Lung Cancer	3
Colorectal Cancer	3
Stage III Lung Cancer AJCC v8	3
Stage IIIB Lung Cancer AJCC v8	3
Extensive-Stage Small-Cell Lung Cancer	2
Small-Cell Lung Cancer	2
Non Small Cell Lung Cancer NSCLC	2
Esophagogastric Junction	2
Non Small Cell Lung Carcinoma NSCLC	2
Small-cell Lung Cancer	2
Glioma	2
Urinary Bladder Neoplasms	2
Unresectable Hepatocellular Carcinoma	2
Advanced Biliary Tract Cancer	2
Non-small Cell Lung Cancer Stage III	2
Small Cell Lung Cancer Limited Stage	2
Intrahepatic Cholangiocarcinoma	2
Endometrial Cancer	2
Hepatocellular Carcinoma Non-resectable	2
Advanced Biliary Tract Carcinoma	2
Ovarian Cancer	2
Pancreatic Cancer	2
Hepatocellular Cancer	2
Lung Non-Small Cell Carcinoma	2
Stage IIIA Lung Cancer AJCC v8	2
HCC - Hepatocellular Carcinoma	2
Tremelimumab	2
Oropharyngeal Cancer	1
Non-small Cell Lung Cancer (NSCLC)	1
Advanced or Metastatic Non-Small Cell Lung Cancer	1
Triple Negative Breast Neoplasms	1
Gastrointestinal Neoplasms	1
Papillary Renal Cell Carcinoma	1
Lung Neoplasms	1
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	1
High-risk Muscle Invasive Urothelial Carcinoma	1
Non-small Cell Lung Cancer NSCLC	1
Neoplasms	1
Advanced Solid Tumors	1
Melanoma	1
Urothelial Cancer	1
Non-muscle-invasive Bladder Cancer	1
Endometrial Neoplasms	1
Neuroendocrine Carcinomas	1
Solid Tumor Show to Express DLL3	1
Metastatic Microsatellite-stable Colorectal Cancer	1
Locally Advanced or Metastatic Non-Small Cell Lung Cancer	1
Non-Small-Cell Lung Carcinoma NSCLC	1
Unresectable Locally Advanced Urothelial Cancer	1
Metastatic Urothelial Cancer	1
Non-Muscle- Invasive Bladder Cancer	1
Locally Advanced or Metastatic Solid Tumours	1
Chondrosarcoma	1
Any Solid Tumor	1
Advanced Ovarian Cancer	1
Small Cell Lung Carcinoma Extensive Disease	1
Advanced or Metastatic NSCLC	1
Esophageal Squamous Cell Carcinoma	1
Extensive Stage Small Cell Lung Cancer	1
Extensive Stage Small-cell Lung Cancer	1
Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Urothelial Carcinoma	1
Head and Neck Squamous Cell Carcinoma	1
Gall Bladder Cancer	1
Biliary Tract Cancers (BTC)	1
Liver Cancer	1
Pancreas Cancer	1
Borderline Resectable Carcinoma	1
SCLC, Limited Stage	1
Intrahepatic Cholangiocarcinoma (Icc)	1
HAIC	1
Gallbladder Cancer Unresectable	1
Resectable Biliary Tract Cancer	1
Advanced Solid Tumours	1
Gastric	1
Esophagogastric Adenocarcinoma	1
Epithelial Ovarian Cancer	1
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	1
Esophagus Adenocarcinoma	1
Extrahepatic Cholangiocarcinoma	1
Unresectable Perihilar or Ductal CCA	1
Anal Cancer	1
Anal Carcinoma	1
Anal Cancer Stage III	1
Anal Cancer Stage II	1
HCC	1
Immune Checkpoint Inhibitors	1
Methotrexate	1
Vinblastine	1
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer	1
a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status	1
Luminal B	1
Triple Negative Breast Cancer	1
Metastatic Pancreatic Adenocarcinoma	1
Small Cell Lung Cancer Extensive Stage	1
Early Small (cT1N0) Triple Negative Breast Cancer	1
Non-small Cell Lung Cancer Stage III Unresectable	1
Oropharyngeal Squamous Cell Carcinoma	1
Unspecified Adult Solid Tumor, Protocol Specific	1
Bladder Cancer	1
Advanced or Recurrent Endometrial Cancer	1
PDL1 Gene Mutation	1
Stage IV	1
Oligometastasis	1
Respiratory Tract Neoplasm	1
Microsatellite Instability	1
Triple Negative Breast Cancer Metastatic	1
Extrapulmonary Small Cell Carcinoma	1
Resectable Colorectal Carcinoma	1
Non-small-cell Lung Cancer Patients	1
Pulmonary Large-cell Neuroendocrine Carcinoma	1
Oncology	1
Infusion Reaction	1
Tumors	1
Neoplasm	1
Neoplasia	1
Metastatic Pancreatic Cancer	1
Solid Tumours	1
NSCLC Stage IV	1
NSCLC Stage IIIB	1
Non Small Cell Lung Cancer Stage III	1
Solid Malignancies	1
Endometrial Adenocarcinoma	1
Endometrial Mixed Cell Adenocarcinoma	1
Endometrial Serous Adenocarcinoma	1
Endometrial Undifferentiated Carcinoma	1
Locally Advanced Pancreatic Carcinoma	1
Stage II Pancreatic Cancer AJCC v8	1
Stage III Pancreatic Cancer AJCC v8	1
Unresectable Pancreatic Carcinoma	1
Pancreatic Ductal Adenocarcinoma	1
Mismatch Repair Proficient Colorectal Cancer	1
Pancreatic Adenocarcinoma	1
Leiomyosarcoma	1
Gastroesophageal Adenocarcinoma	1
Stage III Hepatocellular Carcinoma AJCC v8	1
Stage IV Hepatocellular Carcinoma AJCC v8	1
Metastatic Colorectal Carcinoma	1
Metastatic Lung Non-Small Cell Carcinoma	1
Stage IV Colorectal Cancer AJCC v7	1
Stage IV Lung Non-Small Cell Cancer AJCC v7	1
Solid Tumor	1
IDH Mutation	1
Lung Cancer Metastatic	1
Gynaecological Cancers	1
Locally Advanced Lung Non-Small Cell Carcinoma	1
Stage IIB Lung Cancer AJCC v8	1
Stage II Lung Cancer AJCC v8	1
Renal Pelvis and Ureter Urothelial Carcinoma	1
Locally Advanced Bladder Urothelial Carcinoma	1
Locally Advanced Renal Pelvis Urothelial Carcinoma	1
Locally Advanced Ureter Urothelial Carcinoma	1
Locally Advanced Urethral Urothelial Carcinoma	1
Recurrent Lung Non-Small Cell Carcinoma	1
Fallopian Tube Mucinous Adenocarcinoma	1
Ovarian Seromucinous Carcinoma	1
Platinum-Refractory Fallopian Tube Carcinoma	1
Platinum-Refractory Ovarian Carcinoma	1
Bladder Urothelial Carcinoma	1
Stage III Bladder Cancer AJCC v8	1
CLDN18.2-Positive Gastric Cancer	1
CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma	1
Breast Neoplasms	1
DNA Damage Repair Deficiency	1
Advanced Cancer	1
Immunotherapy	1
Gallbladder Cancer	1
Potentially Resectable Stage II/IIIa NSCLC	1
Stomach Neoplasms	1
Stomach Cancer, Adenocarcinoma	1
Proton Radiotherapy	1
Radiotherapy	1
Premenopausal Breast Cancer	1
ER Positive Breast Cancer	1
Solid Tumor, Adult	1
Esophageal Cancer	1
Anatomic Stage II Breast Cancer AJCC v8	1
Anatomic Stage III Breast Cancer AJCC v8	1
HER2-Negative Breast Carcinoma	1
Hormone Receptor-Positive Breast Carcinoma	1
Advanced Malignant Solid Neoplasm	1
Metastatic Malignant Solid Neoplasm	1
Unresectable Malignant Solid Neoplasm	1
Resectable Hepatocellular Carcinoma	1
Metastatic or Locally Advanced NSCLC	1
Bile Duct Cancer	1
Cholangiocarcinoma Non-resectable	1
Cholangiocarcinoma Metastatic	1
Lung Adenocarcinoma	1
Lung Large Cell Carcinoma	1
Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage IV Lung Cancer AJCC v8	1
Hepatocellular Carcinoma Non-Resectable	1
Hepatocellular Carcinoma Metastatic	1
Pediatric Cancer	1
Solid Tumor Pediatric	1
Hematological Malignancies	1
Ovarian	1
Breast	1
SCLC	1
Gastric Cancers	1
Advanced Non Small Cell Lung Cancer	1
Large Cell Neuroendocrine Carcinoma of the Lung	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	84	19
Clinical trials in South Korea	82	21
Clinical trials in France	79	22
Clinical trials in Spain	79	20
Clinical trials in Canada	74	19
Clinical trials in Italy	67	23
Clinical trials in China	67	26
Clinical trials in Germany	60	14
Clinical trials in Taiwan	58	17
Clinical trials in Japan	55	13
Clinical trials in Poland	49	11
Clinical trials in Australia	45	17
Clinical trials in Brazil	44	12
Clinical trials in UK	43	12
Clinical trials in Belgium	41	11
Clinical trials in Turkey	38	13
Clinical trials in Netherlands	37	13
Clinical trials in Mexico	32	7
Clinical trials in Israel	32	9
Clinical trials in India	26	8
Clinical trials in Austria	18	4
Clinical trials in Switzerland	17	4
Clinical trials in Singapore	15	5
Clinical trials in Czechia	13	4
Clinical trials in Portugal	12	4
Clinical trials in Denmark	11	1
Clinical trials in Sweden	10	4
Clinical trials in Egypt	8	2
Clinical trials in Ireland	5	2
Clinical trials in Norway	5	1
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Durvalumab trials

How many clinical trials are testing Durvalumab?

220 current trials in our USA, South Korea, France, Spain, Canada, Italy, China, Germany, Taiwan, Japan, Poland, Australia, Brazil, UK, Belgium, Turkey, Netherlands, Mexico, Israel, India, Austria, Switzerland, Singapore, Czechia, Portugal, Denmark, Sweden, Egypt, Ireland and Norway registers name Durvalumab (also registered as MEDI 4736) as a drug or biological intervention, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Durvalumab trials recruiting patients?

Yes. 84 of the 220 trials are recruiting: 19 with sites in USA, 21 with sites in South Korea, 22 with sites in France, 20 with sites in Spain, 19 with sites in Canada, 23 with sites in Italy, 26 with sites in China, 14 with sites in Germany, 17 with sites in Taiwan, 13 with sites in Japan, 11 with sites in Poland, 17 with sites in Australia, 12 with sites in Brazil, 12 with sites in UK, 11 with sites in Belgium, 13 with sites in Turkey, 13 with sites in Netherlands, 7 with sites in Mexico, 9 with sites in Israel, 8 with sites in India, 4 with sites in Austria, 4 with sites in Switzerland, 5 with sites in Singapore, 4 with sites in Czechia, 4 with sites in Portugal, 1 with sites in Denmark, 4 with sites in Sweden, 2 with sites in Egypt, 2 with sites in Ireland and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Durvalumab clinical trials?

AstraZeneca (70), National Cancer Institute (NCI) (11), Canadian Cancer Trials Group (8) and Amgen (5), among 94 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Durvalumab clinical trials in Ireland?

Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Durvalumab licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Durvalumab, for example IMFINZI 50 mg/ml concentrate for solution for infusion. (AstraZeneca AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Durvalumab shortage?

Not in the lists we track: Durvalumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Durvalumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Durvalumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Durvalumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Durvalumab clinical trials

Where Durvalumab is approved

What health systems spend on Durvalumab

How Durvalumab works

NICE appraisals of Durvalumab

Patient leaflets for Durvalumab

Reference identifiers for Durvalumab

Trials by status

Trials by phase

Clinical trials of Durvalumab

Durvalumab in the EU trials register (CTIS)

Durvalumab across our data

Licensed in Ireland (HPRA)

Supply shortages

Conditions studied with Durvalumab

Sponsors

By country register

Related compounds

In the same trials as Durvalumab

Other compounds in Hepatocellular Carcinoma trials

Questions about Durvalumab trials

How this page is built